Combination antithrombotic management for NON-ST segment elevation acute coronary syndromes

Research output: Contribution to journalArticle

Abstract

Patients with non-ST segment elevation acute coronary syndromes (NSTEACS) are at high risk for subsequent thrombotic events. Combination antithrombotic management with anticoagulant and antiplatelet medications can improve outcomes in these high-risk patients. If an early invasive strategy is planned, unfractionated heparin or bivalirudin are the anticoagulants of choice, whereas in those in whom an early conservative strategy is planned enoxaparin or fondaparinux may be preferred. All patients with NSTEACS should receive aspirin and continue it indefinitely unless they cannot tolerate it. A second antiplatelet agent should be administered both for an early invasive or early conservative strategy.

Original languageEnglish (US)
Pages (from-to)553-571
Number of pages19
JournalInterventional Cardiology Clinics
Volume2
Issue number4
DOIs
StatePublished - Oct 2013

Fingerprint

Acute Coronary Syndrome
Anticoagulants
Enoxaparin
Platelet Aggregation Inhibitors
Aspirin
Heparin

Keywords

  • Anticoagulation
  • Antiplatelet agents
  • Non-ST segment elevation acute coronary syndrome
  • Outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{2997b196173e49b79eb0b00db3b490d4,
title = "Combination antithrombotic management for NON-ST segment elevation acute coronary syndromes",
abstract = "Patients with non-ST segment elevation acute coronary syndromes (NSTEACS) are at high risk for subsequent thrombotic events. Combination antithrombotic management with anticoagulant and antiplatelet medications can improve outcomes in these high-risk patients. If an early invasive strategy is planned, unfractionated heparin or bivalirudin are the anticoagulants of choice, whereas in those in whom an early conservative strategy is planned enoxaparin or fondaparinux may be preferred. All patients with NSTEACS should receive aspirin and continue it indefinitely unless they cannot tolerate it. A second antiplatelet agent should be administered both for an early invasive or early conservative strategy.",
keywords = "Anticoagulation, Antiplatelet agents, Non-ST segment elevation acute coronary syndrome, Outcomes",
author = "Jayant Bagai and Subhash Banerjee and Brilakis, {Emmanouil S.}",
year = "2013",
month = "10",
doi = "10.1016/j.iccl.2013.05.002",
language = "English (US)",
volume = "2",
pages = "553--571",
journal = "Interventional Cardiology Clinics",
issn = "2211-7458",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Combination antithrombotic management for NON-ST segment elevation acute coronary syndromes

AU - Bagai, Jayant

AU - Banerjee, Subhash

AU - Brilakis, Emmanouil S.

PY - 2013/10

Y1 - 2013/10

N2 - Patients with non-ST segment elevation acute coronary syndromes (NSTEACS) are at high risk for subsequent thrombotic events. Combination antithrombotic management with anticoagulant and antiplatelet medications can improve outcomes in these high-risk patients. If an early invasive strategy is planned, unfractionated heparin or bivalirudin are the anticoagulants of choice, whereas in those in whom an early conservative strategy is planned enoxaparin or fondaparinux may be preferred. All patients with NSTEACS should receive aspirin and continue it indefinitely unless they cannot tolerate it. A second antiplatelet agent should be administered both for an early invasive or early conservative strategy.

AB - Patients with non-ST segment elevation acute coronary syndromes (NSTEACS) are at high risk for subsequent thrombotic events. Combination antithrombotic management with anticoagulant and antiplatelet medications can improve outcomes in these high-risk patients. If an early invasive strategy is planned, unfractionated heparin or bivalirudin are the anticoagulants of choice, whereas in those in whom an early conservative strategy is planned enoxaparin or fondaparinux may be preferred. All patients with NSTEACS should receive aspirin and continue it indefinitely unless they cannot tolerate it. A second antiplatelet agent should be administered both for an early invasive or early conservative strategy.

KW - Anticoagulation

KW - Antiplatelet agents

KW - Non-ST segment elevation acute coronary syndrome

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84884979655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884979655&partnerID=8YFLogxK

U2 - 10.1016/j.iccl.2013.05.002

DO - 10.1016/j.iccl.2013.05.002

M3 - Article

C2 - 28582183

AN - SCOPUS:84884979655

VL - 2

SP - 553

EP - 571

JO - Interventional Cardiology Clinics

JF - Interventional Cardiology Clinics

SN - 2211-7458

IS - 4

ER -